Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives $119.67 Consensus PT from Analysts

Axsome Therapeutics, Inc. (NASDAQ:AXSM) has earned an average recommendation of “Moderate Buy” from the twelve brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $119.67.

A number of analysts have weighed in on AXSM shares. Cantor Fitzgerald reissued an “overweight” rating and set a $107.00 price objective on shares of Axsome Therapeutics in a report on Wednesday, April 10th. Robert W. Baird began coverage on shares of Axsome Therapeutics in a research report on Tuesday, March 19th. They issued an “outperform” rating and a $108.00 price target for the company. Royal Bank of Canada upped their price target on shares of Axsome Therapeutics from $123.00 to $128.00 and gave the company an “outperform” rating in a research report on Tuesday, March 26th. Citigroup upped their price target on shares of Axsome Therapeutics from $125.00 to $127.00 and gave the company a “buy” rating in a research report on Tuesday, March 26th. Finally, Guggenheim upped their price objective on shares of Axsome Therapeutics from $110.00 to $125.00 and gave the stock a “buy” rating in a research report on Wednesday, February 21st.

Insider Buying and Selling at Axsome Therapeutics

In other news, COO Mark L. Jacobson sold 24,662 shares of the stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $77.24, for a total transaction of $1,904,892.88. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, COO Mark L. Jacobson sold 24,662 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $77.24, for a total value of $1,904,892.88. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Roger Jeffs sold 29,976 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $69.70, for a total transaction of $2,089,327.20. Following the completion of the transaction, the director now owns 120,756 shares in the company, valued at approximately $8,416,693.20. The disclosure for this sale can be found here. 24.50% of the stock is owned by insiders.

Institutional Trading of Axsome Therapeutics

Several large investors have recently bought and sold shares of AXSM. Harbour Investments Inc. boosted its holdings in Axsome Therapeutics by 461.5% in the second quarter. Harbour Investments Inc. now owns 365 shares of the company’s stock worth $26,000 after purchasing an additional 300 shares during the period. Washington Trust Advisors Inc. bought a new stake in Axsome Therapeutics in the fourth quarter valued at $26,000. Fifth Third Bancorp lifted its stake in Axsome Therapeutics by 100.0% in the third quarter. Fifth Third Bancorp now owns 400 shares of the company’s stock valued at $28,000 after buying an additional 200 shares during the last quarter. Captrust Financial Advisors lifted its stake in Axsome Therapeutics by 582.0% in the first quarter. Captrust Financial Advisors now owns 757 shares of the company’s stock valued at $31,000 after buying an additional 646 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in shares of Axsome Therapeutics by 141.1% during the first quarter. Tower Research Capital LLC TRC now owns 815 shares of the company’s stock valued at $50,000 after purchasing an additional 477 shares in the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Stock Up 1.3 %

Shares of NASDAQ:AXSM opened at $69.71 on Monday. The firm’s 50 day moving average price is $78.69 and its 200 day moving average price is $75.10. The stock has a market cap of $3.30 billion, a price-to-earnings ratio of -13.41 and a beta of 1.13. Axsome Therapeutics has a fifty-two week low of $55.02 and a fifty-two week high of $98.40. The company has a quick ratio of 3.52, a current ratio of 3.63 and a debt-to-equity ratio of 0.93.

Axsome Therapeutics (NASDAQ:AXSM) last issued its earnings results on Tuesday, February 20th. The company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($1.21) by $0.48. The firm had revenue of $71.53 million for the quarter, compared to analysts’ expectations of $70.38 million. Axsome Therapeutics had a negative net margin of 88.41% and a negative return on equity of 70.67%. As a group, equities research analysts predict that Axsome Therapeutics will post -3.72 earnings per share for the current fiscal year.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.